Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ABPNASDAQ:MRKRNASDAQ:NRSNNASDAQ:PALI On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeABPAbpro$0.24-8.2%$0.41$0.22▼$13.00$12.47M-0.07197,516 shs570,557 shsMRKRMarker Therapeutics$1.19-3.3%$1.27$0.95▼$5.99$12.74M1.5461,056 shs37,490 shsNRSNNeuroSense Therapeutics$0.98+1.0%$1.04$0.51▼$1.50$13.39M1.36239,535 shs53,685 shsPALIPalisade Bio$0.78+2.7%$0.77$0.60▼$9.09$3.32M1.5538,079 shs76,055 shs20 Stocks to Sell NowGet This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceABPAbpro-8.15%-26.34%-42.32%-76.82%+23,879,900.00%MRKRMarker Therapeutics-3.25%+1.71%-3.25%-38.02%-70.62%NRSNNeuroSense Therapeutics+1.03%-0.70%+5.39%-7.55%-27.41%PALIPalisade Bio+2.66%+9.68%+14.00%-45.73%-87.13%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationABPAbproN/AN/AN/AN/AN/AN/AN/AN/AMRKRMarker Therapeutics4.5478 of 5 stars3.85.00.03.94.10.80.6NRSNNeuroSense Therapeutics1.1238 of 5 stars0.05.00.00.02.51.70.0PALIPalisade Bio3.2421 of 5 stars3.55.00.00.03.60.01.3Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceABPAbpro 3.00Buy$4.001,575.04% UpsideMRKRMarker Therapeutics 3.50Strong Buy$13.171,006.44% UpsideNRSNNeuroSense Therapeutics 2.00HoldN/AN/APALIPalisade Bio 3.00Buy$23.002,863.54% UpsideCurrent Analyst Ratings BreakdownLatest PALI, ABP, MRKR, and NRSN Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails4/1/2025MRKRMarker TherapeuticsWBB SecuritiesSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingStrong-Buy ➝ Strong-Buy$12.50 ➝ $12.503/5/2025MRKRMarker TherapeuticsCanaccord Genuity GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$8.002/24/2025ABPAbproMaxim GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$4.002/10/2025MRKRMarker TherapeuticsBrookline Capital ManagementSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeStrong-Buy(Data available from 5/1/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookABPAbpro$183K68.14N/AN/AN/A∞MRKRMarker Therapeutics$6.59M1.93N/AN/A$1.58 per share0.75NRSNNeuroSense TherapeuticsN/AN/AN/AN/A($0.14) per shareN/APALIPalisade Bio$250K13.65N/AN/A$18.29 per share0.04Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateABPAbproN/AN/A0.00∞N/AN/AN/AN/AN/AMRKRMarker Therapeutics-$8.24M-$1.20N/AN/AN/A-179.74%-89.63%-71.62%5/21/2025 (Estimated)NRSNNeuroSense Therapeutics-$11.28M-$0.54N/A∞N/AN/AN/A-590.79%6/23/2025 (Estimated)PALIPalisade Bio-$12.30M-$10.92N/AN/AN/AN/A-148.51%-115.16%5/12/2025 (Estimated)Latest PALI, ABP, MRKR, and NRSN EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/21/2025Q1 2025MRKRMarker Therapeutics-$0.66N/AN/AN/A$0.50 millionN/A5/12/2025N/APALIPalisade Bio-$0.84N/AN/AN/AN/AN/A4/7/2025Q4 2024NRSNNeuroSense Therapeutics-$0.12-$0.06+$0.06-$0.06N/AN/A3/31/2025Q4 2024MRKRMarker Therapeutics-$0.28-$0.42-$0.14-$0.42$5.25 million$1.22 million3/24/2025Q4 2024PALIPalisade Bio-$2.39-$0.69+$1.70-$0.69N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthABPAbproN/AN/AN/AN/AN/AMRKRMarker TherapeuticsN/AN/AN/AN/AN/ANRSNNeuroSense TherapeuticsN/AN/AN/AN/AN/APALIPalisade BioN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioABPAbproN/AN/AN/AMRKRMarker TherapeuticsN/A3.153.15NRSNNeuroSense TherapeuticsN/A0.21N/APALIPalisade BioN/A3.313.31Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipABPAbpro23.30%MRKRMarker Therapeutics22.39%NRSNNeuroSense Therapeutics1.04%PALIPalisade Bio11.79%Insider OwnershipCompanyInsider OwnershipABPAbpro19.80%MRKRMarker Therapeutics14.50%NRSNNeuroSense Therapeutics27.40%PALIPalisade Bio3.28%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableABPAbpro1552.22 million4.57 millionN/AMRKRMarker Therapeutics6010.71 million9.16 millionNot OptionableNRSNNeuroSense Therapeutics1013.67 million9.92 millionNot OptionablePALIPalisade Bio104.40 million2.68 millionNot OptionablePALI, ABP, MRKR, and NRSN HeadlinesRecent News About These CompaniesHyundai’s Next-Gen Hybrid System Offers 45% Boost In Fuel EfficiencyApril 21, 2025 | msn.comPalisade completes dosing in Phase 1b portion of Phase 1a/1n study of PALI-2108April 9, 2025 | markets.businessinsider.comPalisade Bio Completes Dosing in Phase 1a Portion of Ongoing Phase 1a/b Study of PALI-2108April 9, 2025 | globenewswire.comMaxim Group Sticks to Their Buy Rating for Palisade Bio (PALI)March 27, 2025 | markets.businessinsider.comPalisade Bio begins dosing subjects in last cohort of ulcerative colitis drug trialMarch 17, 2025 | finance.yahoo.comPalisade Bio commences dosing in first UC patient cohort in study of PALI-2108March 14, 2025 | markets.businessinsider.comPalisade Bio Reports Encouraging Preliminary Safety and Tolerability Data for PALI-2108 in Phase 1a/b Study for Ulcerative ColitisMarch 14, 2025 | quiverquant.comPalisade Bio Commences Dosing in First Ulcerative Colitis Patient Cohort in Ongoing Phase 1a/b Study of PALI-2108March 14, 2025 | globenewswire.comPalisade Bio Announces Two Abstracts Selected to be Showcased as Poster of Distinction and Poster Presentation at Leading GI Forum, Digestive Disease Week (DDW) 2025March 12, 2025 | globenewswire.comPalisade Bio (PALI) Upgraded to Buy: What Does It Mean for the Stock?March 7, 2025 | zacks.comPalisade Bio Participates in Virtual Investor “What This Means” SegmentMarch 4, 2025 | globenewswire.comPalisade Bio receives cash proceeds from Canada’s SR&ED tax incentive programFebruary 20, 2025 | markets.businessinsider.comPalisade Bio Secures CAD$1.39 Million in SR&ED Funding for PALI-2108 Development EffortsFebruary 20, 2025 | quiverquant.comPalisade Bio, Inc. Announces Receipt of Cash Proceeds from Canada's SR&ED Tax Incentive Program for Reimbursement of Development Costs of PALI-2108 for Treatment of Ulcerative Colitis (UC)February 20, 2025 | globenewswire.comPalisade Bio, Inc. Participates in the Virtual Investor “Top 5 for ‘25” On-Demand ConferenceFebruary 19, 2025 | globenewswire.comPalisade Bio presents preclinical data of PALI-2108February 10, 2025 | markets.businessinsider.comPalisade Bio Presents Positive Preclinical Data for PALI-2108 in Ulcerative Colitis at 2025 Crohn’s and Colitis CongressFebruary 10, 2025 | quiverquant.comPalisade Bio Presents Positive Preclinical Data of PALI-2108 for the Treatment of Ulcerative ColitisFebruary 10, 2025 | globenewswire.comPalisade Bio Selected for Poster Presentation at the 2025 Crohn’s & Colitis CongressJanuary 30, 2025 | markets.businessinsider.comPalisade Bio Selected for Poster Presentation at the 2025 Crohn's & Colitis CongressJanuary 29, 2025 | globenewswire.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimePALI, ABP, MRKR, and NRSN Company DescriptionsAbpro NASDAQ:ABP$0.24 -0.02 (-8.15%) As of 04/30/2025 04:00 PM EasternAbpro Holdings Inc. is a biotechnology company. The company's mission is to improve the lives of mankind facing severe and life-threatening diseases with next-generation antibody therapies. Abpro Holdings Inc., formerly known as Atlantic Coastal Acquisition Corp. II, is based in WOBURN, Mass.Marker Therapeutics NASDAQ:MRKR$1.19 -0.04 (-3.25%) As of 04/30/2025 04:00 PM EasternMarker Therapeutics, Inc., a clinical-stage immuno-oncology company, engages in the development and commercialization of novel T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications. Its multi tumor associated antigen-specific T cell technology is based on the manufacture of non-engineered tumor-specific T cells that recognize multiple tumor-associated antigens. The company also develops MT-401-OTS for the treatment of acute myeloid leukemia; and MT-601 to treat lymphoma and pancreatic cancer. Marker Therapeutics, Inc. is headquartered in Houston, Texas.NeuroSense Therapeutics NASDAQ:NRSN$0.98 +0.01 (+1.03%) As of 04/30/2025 03:48 PM EasternNeuroSense Therapeutics Ltd., a clinical-stage biotechnology company, focuses on discovering and developing treatments for patients suffering from debilitating neurodegenerative diseases in the United States and internationally. The company's lead product is PrimeC, an extended-release oral formulation of a fixed-dose combination of ciprofloxacin and celecoxib, currently under Phase 2b/3 clinical trials for the treatment of amyotrophic lateral sclerosis, and completed Phase 2 clinical trials for the treatment of Alzheimer's, as well as under preclinical studies for the treatment of Parkinson's disease. Its preclinical pipeline includes StabiliC for the treatment of Parkinson's disease; and CogniC for the treatment of Alzheimer's disease. The company was incorporated in 2017 and is headquartered in Herzliya, Israel.Palisade Bio NASDAQ:PALI$0.78 +0.02 (+2.71%) As of 04/30/2025 03:59 PM EasternPalisade Bio, Inc., a clinical-stage biopharmaceutical company, focuses on focuses on developing therapeutics that protect the integrity of the intestinal barrier in the United States. The company's lead therapeutic candidate is PALI-2108, a prodrug PDE4 inhibitor, currently under pre-clinical development as a therapeutic for patients living with inflammatory bowel diseases, including ulcerative colitis and Crohn's disease (CD), as well as develops PALI-1908, an oral, selective PDE4 inhibitor prodrug that is locally bioactivated in the terminal ileum of CD patients, currently in the research stage. It has a research collaboration and license agreement with Giiant Pharma, Inc. for the development, manufacture, and commercialization of its compounds; a license agreement with the Regents of the University of California; a co-development and distribution agreement with Newsoara Biopharma Co., Ltd; and a transformative strategic collaboration with Strand Life Sciences for advancing precision medicine for ulcerative colitis therapy. The company is based in Carlsbad, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Hims & Hers Stock Soars on Novo Nordisk Collaboration 3 Dividend Kings Outshining the Market in 2025 Tesla's Band-Aid Has Been Ripped Off: Rally Mode Engaged Amazon's Earnings Will Make or Break the Stock's Comeback Why D-Wave's Project With Davidson Is a Game-Changer For Quantum NXP Semiconductors: A Buy-and-Hold Stock in the Buy Zone Joby Aviation Shares Eye Breakout After Transition Flight Win Altria’s Resilient Strategy Keeps It a Top Dividend Play in 2025 Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
